专利信息

首页 1 2 3 下页尾页共 29 条记录, 当前第1/3页。

专利标题：(heteroarylmethyl) thiohydantoins as anticancer drugs

The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids also known as uterine leiomyoma leiomyomata. Particularly the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate oxendolone chlormadinone acetate spironolactone osaterone acetate dienogest flutamide hydroxyflutamide nilutamide bicalutamide RU 58841 LGD-2226 MDV3100 BMS-641988 BMS-779333 or ...

专利标题：(Heteroarylmethyl) Thiohydantoins as anticancer drugs

The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-64198...

专利标题：Replacement (heteroaryl methyl) thiohydantoin as cancer therapy drug

专利权人：BAYER SCHERING PHARMA AG;

专利标题：Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs

专利标题：Therapy of prostate cancer with ctla-4 antibodies and hormonal therapy

The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cyproterone flu...

专利标题：With ctla4 antibody and hormonotherapy treatment carcinoma of prostate

专利权人：Pfizer Prod Inc.;

专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy

专利权人：Pfizer Products Incorporated;

The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1 ) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1 ) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cypr...

专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy

专利权人：Pfizer Products Inc.;

The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1. 1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cyproterone fl...

专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy.

专利权人：Pfizer Products Inc.;

The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1 ) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1 ) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cypr...

当前查询条件: [药品] 包含 'Nilutamide'

	查询范围	在当前结果中查询
!	专利类型	发明实用新型外观设计
!	公开号			CN1234
!	申请号			CN1234
!	专利标题		扩展	PHARMA
!	专利权人		扩展	pfizer
	发明人
!	申请日			yyyymmdd
!	公开日			yyyymmdd
	优先权号
!	摘要		扩展	PHARMA
	IPC			A01B

1. US20120238533A1	2012/9/20	US13/395087	2010/9/3
专利标题：(heteroarylmethyl) thiohydantoins as anticancer drugs 专利权人：Bayer Intellectual Property Gmbh; The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids also known as uterine leiomyoma leiomyomata. Particularly the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate oxendolone chlormadinone acetate spironolactone osaterone acetate dienogest flutamide hydroxyflutamide nilutamide bicalutamide RU 58841 LGD-2226 MDV3100 BMS-641988 BMS-779333 or ...

2. US2012238533A1	2012/9/20	US201013395087	2010/9/3
专利标题：(Heteroarylmethyl) Thiohydantoins as anticancer drugs 专利权人：CLEVE ARWED [DE];LUECKING ULRICH [DE];BAEURLE STEFAN [DE];FRITSCH MARTIN [DE];SCHROEDER JENS [DE];IGL BERND-WOLFGANG [DE];BAYER PHARMA AG [DE]; The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids, also known as uterine leiomyoma, leiomyomata. Particularly, the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate, oxendolone, chlormadinone acetate, spironolactone, osaterone acetate, dienogest, flutamide, hydroxyflutamide, nilutamide, bicalutamide, RU 58841, LGD-2226, MDV3100, BMS-64198...

3. CN102481294A	2012/5/30	CN20108039758	2010/9/3
专利标题：Replacement (heteroaryl methyl) thiohydantoin as cancer therapy drug 专利权人：BAYER SCHERING PHARMA AG;

4. WO2011029782A1	2011/3/17	WO2010EP62964	2010/9/3
专利标题：Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs 专利权人：Bayer Schering Pharma Aktiengesellschaft; The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids also known as uterine leiomyoma leiomyomata. Particularly the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate oxendolone chlormadinone acetate spironolactone osaterone acetate dienogest flutamide hydroxyflutamide nilutamide bicalutamide RU 58841 LGD-2226 MDV3100 BMS-641988 BMS-779333 or ...

5. CA2773615A1	2011/3/17	CA20102773615	2010/9/3
专利标题：Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs 专利权人：Bayer Pharma Aktiengesellschaft; The invention refers to the use of androgen receptor antagonists for the treatment and/or prevention of fibroids also known as uterine leiomyoma leiomyomata. Particularly the invention refers to the use of an androgen receptor antagonist being any one of the compounds according to the following list: cyproterone acetate oxendolone chlormadinone acetate spironolactone osaterone acetate dienogest flutamide hydroxyflutamide nilutamide bicalutamide RU 58841 LGD-2226 MDV3100 BMS-641988 BMS-779333 or ...

6. US20080279865A1	2008/11/13	US11/817390	2006/3/3
专利标题：Therapy of prostate cancer with ctla-4 antibodies and hormonal therapy 专利权人：Pfizer, Inc., Pfizer Products, Inc.; The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cyproterone flu...

7. CN101146552A	2008/3/19	CN20068009522	2006/3/3
专利标题：With ctla4 antibody and hormonotherapy treatment carcinoma of prostate 专利权人：Pfizer Prod Inc.;

8. EP1868644A1	2007/12/26	EP20060736896	2006/3/3
专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy 专利权人：Pfizer Products Incorporated; The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1 ) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1 ) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cypr...

9. KR20070108259A	2007/11/8	KR20077021945	2007/9/21
专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy 专利权人：Pfizer Products Inc.; The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1. 1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cyproterone fl...

10. MX2007010603A	2007/10/18	MX20070010603	2007/8/30
专利标题：Therapy of prostate cancer with ctla4 antibodies and hormonal therapy. 专利权人：Pfizer Products Inc.; The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody or an antigen-binding portion thereof particularly a human antibody to human CTLA4 e.g. antibody 3.1.1 4.1.1 4.8.1 4.10.2 4.13.1 4.14.3 6.1.1 ticilimumab (also known as 11.2.1 ) 11.6.1 11.7.1 12.3.1.1 12.9.1.1 and ipilimumab (also known as MDX-010 and 10D1 ) in combination with hormonal therapy. Hormonal therapy agents include inter alia an anti-androgen (e.g. megestrol cypr...

下载范围

下载内容